Clinical Trials in Prato, Italy
2 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca895 enrolled283 locationsNCT04862663
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled293 locationsNCT06926868
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 3
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Breast Cancer
Daiichi Sankyo250 enrolled86 locationsNCT05950945
Recruiting
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Metastatic Breast Cancer
European Institute of Oncology1,000 enrolled37 locationsNCT06994377
Recruiting
EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase
Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS1,000 enrolled29 locationsNCT06894173
Recruiting
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
Metastatic Breast CancerHER2-negative Breast CancerER Positive Breast Cancer
Fondazione Sandro Pitigliani150 enrolled1 locationNCT04660435
Recruiting
Phase 3
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
Metastatic Breast CancerAdvanced Breast CancerQuality of Life+2 more
Region Örebro County495 enrolled12 locationsNCT06044623